7-150293323-C-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001164458.2(ACTR3C):c.142G>A(p.Val48Ile) variant causes a missense change. The variant allele was found at a frequency of 0.0000151 in 1,586,280 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_001164458.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ACTR3C | NM_001164458.2 | c.142G>A | p.Val48Ile | missense_variant | 3/8 | ENST00000683684.1 | NP_001157930.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ACTR3C | ENST00000683684.1 | c.142G>A | p.Val48Ile | missense_variant | 3/8 | NM_001164458.2 | ENSP00000507618.1 |
Frequencies
GnomAD3 genomes AF: 0.0000462 AC: 7AN: 151454Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000193 AC: 4AN: 206904Hom.: 0 AF XY: 0.0000273 AC XY: 3AN XY: 109780
GnomAD4 exome AF: 0.0000118 AC: 17AN: 1434826Hom.: 0 Cov.: 33 AF XY: 0.00000985 AC XY: 7AN XY: 710788
GnomAD4 genome AF: 0.0000462 AC: 7AN: 151454Hom.: 0 Cov.: 31 AF XY: 0.0000541 AC XY: 4AN XY: 73884
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 08, 2024 | The c.142G>A (p.V48I) alteration is located in exon 3 (coding exon 2) of the ACTR3C gene. This alteration results from a G to A substitution at nucleotide position 142, causing the valine (V) at amino acid position 48 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at